Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 246-998-3 | CAS number: 25448-25-3
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Neurotoxicity
Administrative data
- Endpoint:
- neurotoxicity: short-term oral
- Type of information:
- migrated information: read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- key study
- Study period:
- 2005
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: This study was conducted in compliance with the OECD (1998) and EPA TSCA (1989) Good Laboratory Practices Guidance. (Author)
Cross-reference
- Reason / purpose for cross-reference:
- reference to same study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 005
- Report date:
- 2005
Materials and methods
Test guideline
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- other: OECD Guideline 422 (Combined Repeated Dose Toxicity Study with the Reproduction / Developmental Toxicity Screening Test)
- Deviations:
- yes
- Remarks:
- See Principles of Method
- Principles of method if other than guideline:
- The study exceeded the OECD 422 guideline design by extending dosing of F0 females through Day 21 of lactation (total of 8-9 weeks). The original study design included evaluation of 28 day exposure in females (to correlate with 28 day exposure in males), male and female recovery groups, and extended post weaning evaluation (70 days) in F1 offspring. The final study report contains all sections required by the OECD 422 guideline (1996), including data collected on the FO parental animals and on the Fl offspring to their weaning on pnd 21 (an extension beyond the specified termination on pnd 4 in the OECD 422 [1996] testing guideline). The data collected on the 28-day females, the recovery males and females, and on the F1 offspring animals after weaning were collected as initially specified in the protocol but were not included in the study report. The data not reported (and wet tissues, blocks and slides not processed or examined) were retained in the study records and archived with the study upon the submission of the final report.
- GLP compliance:
- yes
- Limit test:
- yes
Test material
- Reference substance name:
- Triisodecyl phosphite
- EC Number:
- 246-998-3
- EC Name:
- Triisodecyl phosphite
- Cas Number:
- 25448-25-3
- Molecular formula:
- C30H63O3P
- IUPAC Name:
- tris(2-methylnonyl) phosphite
- Test material form:
- other: liquid
- Details on test material:
- - Name of test material (as cited in study report): TDP- Analytical purity: > 99%- Lot/batch No.: Doverphos 6, Batch 162T041801
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS - Source: Charles River Breeding Laboratories, Raleigh, NC - Age at study initiation: 10 weeks - Housing: The animals were individually housed upon arrival, during the acclimation period, and upon the initiation of the treatment period in solid-bottom polycarbonate cages with stainless-steel wire lids (Laboratory Products, Rochelle Park, NJ) with Sani-Chip® cage litter (P.J. Murphy Forest Products Corp., Montville, NJ). Study animals were housed 2 per cage (1 male: 1 female from the same dose group) during the mating period. Females were caged individually once they were successfully mated (or at the end of the mating period) and throughout gestation. Females were housed with their litters throughout the lactation period. Randomly selected Fl weanlings (10/sex/group), males, and females were singly housed during the postweaning exposure period. - Diet (e.g. ad libitum): Pelleted Purina Certified Rodent Diet® (No. 5002, PMI Feeds, Inc., St. Louis, MO was available ad libitum. - Water (e.g. ad libitum): Tap water (source: City of Durham, Department of Water Resources, Durham, NC) was available ad libitum in plastic water bottles with butyl rubber stoppers and stainless-steel sipper tubes. - Acclimation period: 1 week ENVIRONMENTAL CONDITIONS - Temperature (°C): 71.1 to 76.2°F - Humidity (%): 37.2% to 69.6%. - Photoperiod (hrs dark / hrs light): 12-hour light cycle per day
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- corn oil
- Details on exposure:
- Male and female CD (Sprague-Dawley(SD)) F0 rats were administered TDP orally by gavage at 0, 50, 250 and 1000 mg/kg/day at a dose volume of 5 ml/kg/day in Mazola® corn oil, 10 animals/sex/dose, for 2 weeks of prebreed exposure (males and females), 2 weeks of mating (males and females) and 3 weeks of gestation and lactation each (F0 females).
- Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Homogeneity and stability studies were run on TDP in corn oil at concentrations of 10, 50, and 200 mg/mL (TDP in corn oil). The 50 and 200 mg/mL concentrations were prepared weekly as they were found to be stable. The 10 mg/mL concentration was prepared daily due to stability concerns. Dosage formulations analyzed during the study were found to be 90.8-110% of nominal concentrations.
- Duration of treatment / exposure:
- F0 males - 28 daysF0 females - 8-9 weeks (14 days prebreed, mating, gestation, lactation through pnd 21)
- Frequency of treatment:
- Once daily/7days per week
Doses / concentrations
- Remarks:
- Doses / Concentrations:0, 50, 250 and 1000 mg/kg/day Basis:actual ingested
- No. of animals per sex per dose:
- 10
- Control animals:
- yes, concurrent vehicle
Examinations
- Observations and clinical examinations performed and frequency:
- Parental animals: Observations and examinations CAGE SIDE OBSERVATIONS: Yes - Time schedule: at least once daily for F0 males and females until necropsy. DETAILED CLINICAL OBSERVATIONS: Yes - Time schedule: baseline during quarantine and then weekly BODY WEIGHT: Yes - Time schedule for examinations: Males - on study Day 0, then weekly and at necropsy; Females - on study Days 0, 7, and 14 (prebreed), and on Gesation Days 0, 7, 14, and 20, and on Lactation Days 0, 4, 7, 14 and 21. FOOD CONSUMPTION: Yes, at the same intervals as body weight. HAEMATOLOGY: Yes - Time schedule for collection of blood: Males - Day 28; Females - Day 13 - Animals fasted: Yes - How many animals: 5 per sex per group CLINICAL CHEMISTRY: Yes (males only) - Time schedule for collection of blood: Day 28 - Animals fasted: Yes - How many animals: 5 males per group URINALYSIS: Yes (males only) - Time schedule for collection of urine: Day 28 - Metabolism cages used for collection of urine: Yes
- Neurobehavioural examinations performed and frequency:
- FUNCTIONAL OBSERVATIONAL BATTERY: Yes - Functional Observational Battery (FOB) including home cage observations, handling observations, open field observations, sensory and neuromuscular observations and physiological observations, was performed on all animals once during quarantine and once per week for F0 animals during prebreed and mating (for both sexes), and during gestation and until lactation Day 21 (F0 females). LOCOMOTOR ACTIVITY: YesAUDITORY STARTLE REFLEX HABITUATION: Yes- Motor activity, auditory startle response and grip strength conducted at study termination (Day 28 for males; Week 8-9 for females)
- Sacrifice and (histo)pathology:
- All F0 parental animals were necropsied with complete histologic evaluation of 5 selected males and females in the 0 and 1000 mg/kg/day groups.
Results and discussion
Results of examinations
- Clinical signs:
- no effects observed
- Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- no effects observed
- Behaviour (functional findings):
- no effects observed
- Gross pathological findings:
- no effects observed
- Neuropathological findings:
- no effects observed
- Description (incidence and severity):
- brain and sciatic nerve (F0 animals)
- Other effects:
- no effects observed
- Description (incidence and severity):
- Migrated information from 'Further observations for developmental neurotoxicity study'Details on results (for developmental neurotoxicity):F1 Offspring Toxicity Through Weaning (pnd 21):There was no evidence of Fl offspring toxicity either at birth or during lactation. There were no effects on survival indices, litter size, sex ratio/litter, or pup deaths across any groups. Body weights of pups per litter (all pups or separately by sex) were equivalent across all groups for all timepoints, except for significant increases in female and all pup (but not male pup) body weights/litter at 50 mg/kg/day on pnd 0, most likely due to the slightly reduced live litter size (13.1) at this dose relative to the control live litter size (15.8). There were no effects on anogenital distance for either sex at birth. (migrated information)
Effect levels
open allclose all
- Dose descriptor:
- NOAEL
- Effect level:
- >= 1 000 mg/kg bw/day
- Sex:
- male/female
- Remarks on result:
- other: Generation: other: - parental (migrated information)
- Dose descriptor:
- NOAEL
- Effect level:
- >= 1 000 mg/kg bw/day
- Sex:
- male/female
- Remarks on result:
- other: Generation: offspring (migrated information)
Applicant's summary and conclusion
- Conclusions:
- TDP administered by gavage once daily at 0, 50, 250 and 1000 mg/kg/day to parental F0 CD (SD) rats, 10/sex/group through prebreed, mating, gestation and F1 lactation resulted in essentially no treatment or dose related adult F0 parental toxicity at any dose at any time. Reproductive toxicity was not present in F0 males or females. There was also no F1offspring toxicity observed postnatally through the weanling necropsy. Therefore, the F0 male and female systemic no observable adverse effect level (NOAEL) was at or above 1000mg/kg/day for males and females. The NOAELs for F0 reproductive toxicity were observed at or above 1000 mg/kg/day for males and females. The NOAELs for F1 offspring toxicity during lactation were also at or above 1000 mg/kg/day for males and females. (Author)
- Executive summary:
In a Guideline (modified OECD 422) GLP study with extended treatment to Day 21 of lactation, TDP administered by gavage once daily at 0, 50, 250, 1000 mg/kg/day to parental FO CD® (SD) rats, 10/sex/group, through prebreed, mating, gestation, and Fl lactation, resulted in essentially no treatment- or dose-related adult FO parental toxicity at any dose at any time. There was no evidence of F0 parental neurotoxicity based on functional observational batteries, motor activity, auditory startle response and grip strength. Reproductive toxicity was not present in FO males or females. There was also no Fl offspring toxicity observed postnatally through the weanling necropsy. Therefore, the FO male (28 days) and female (8 -9 weeks) systemic no observable adverse effect level (NOAEL), including neurotoxicity, was at or above 1000 mg/kg/day. The NOAELs for FO reproductive toxicity were at or above 1000 mg/kg/day for males and females. The NOAELs for Fl offspring toxicity during lactation were also at or above 1000 mg/kg/day for males and females.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.